Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 10:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Controlled Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

NCT01666652
View directory record Official record
Conditions
Dengue Fever
Interventions
4 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS03B1 adjuvant, Phosphate buffered saline, 1 µg TDENV-PIV with Alum adjuvant, 1 µg TDENV-PIV with AS01E1 adjuvant
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

NCT00192452
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 24, 2006 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Results available

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

NCT04860830
View directory record Official record
Conditions
Schizophrenia
Interventions
Iclepertin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Anaheim, California • Culver City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

NCT04652700
View directory record Official record
Conditions
HIV Preexposure Prophylaxis
Interventions
ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
16 Years and older · Male only
Enrollment
494 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

NCT00380900
View directory record Official record
Conditions
Healthy Subjects, Osteoarthritis
Interventions
AGG-523
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention

NCT02561000
View directory record Official record
Conditions
Arterial Occlusive Diseases, Coronary Artery Disease, Coronary Disease, Arteriosclerosis, Heart Diseases, Myocardial Ischemia, Vascular Diseases, Acute Coronary Syndrome
Interventions
PZ-128, Placebo
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts • Worcester, Massachusetts • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 9, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional Results available

IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy

NCT02697292
View directory record Official record
Conditions
Autoimmune Epilepsy
Interventions
Intravenous Immunoglobulin, Placebos, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study to Determine Anti-Asthmatic Effect of Esomeprazole Magnesium; Nexium Reflux Asthma

NCT00317044
View directory record Official record
Conditions
Asthma, GERD
Interventions
Esomeprazole, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects

NCT05032144
View directory record Official record
Conditions
Healthy
Interventions
STSA-1002 injection, Placebo
Drug
Lead sponsor
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease

NCT01241344
View directory record Official record
Conditions
Adenovirus Disease
Interventions
Brincidofovir, Placebo
Drug · Other
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
3 Months to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
30
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 9, 2026, 10:59 AM EDT
Not yet recruiting Phase 4 Interventional

Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty

NCT07598734
View directory record Official record
Conditions
Sleep Quality Post-TKA, Postoperative Knee Function, Quality of Life After Primary TKA
Interventions
Doxepin 6 mg, Ramelteon 8 mg, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BT-600 Single and Multiple Ascending Oral Doses in Healthy Adult Subjects

NCT06275464
View directory record Official record
Conditions
Healthy
Interventions
BT-600, BT-600 Placebo
Combination Product
Lead sponsor
Biora Therapeutics, Inc.
Industry
Eligibility
19 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Sep 9, 2026, 10:59 AM EDT
Terminated Phase 3 Interventional

Modafinil in Opioid Induced Sedation

NCT00267332
View directory record Official record
Conditions
Cancer, Pain
Interventions
Modafinil
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus

NCT03467932
View directory record Official record
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 3 Interventional

A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

NCT06584916
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Orforglipron, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Pelham, Alabama • Santa Ana, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Attitudes & College Experiences

NCT04026633
View directory record Official record
Conditions
Alcohol Abuse
Interventions
CAA, Control
Behavioral
Lead sponsor
Brooklyn College of the City University of New York
Other
Eligibility
18 Years to 26 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652
View directory record Official record
Conditions
Heart Failure
Interventions
HeartMate II (HMII), Warfarin, acetylsalicylic acid (ASA) therapy
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
50 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2022 · Synced Sep 9, 2026, 10:59 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

NCT07690371
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis
Interventions
Rezpegaldesleukin, Placebo
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Fountain Valley, California • Los Angeles, California • Boca Raton, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 9, 2026, 10:59 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Homeopathic Drug Provings

NCT00809263
View directory record Official record
Conditions
Healthy
Interventions
homeopathic remedy
Drug
Lead sponsor
Integrative Medicine Institute
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 12, 2014 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional

Study of NGX267 Oral Capsules in Patients With Xerostomia Associated With Sjorgren's Syndrome

NCT00637793
View directory record Official record
Conditions
Xerostomia, Sjogren's Syndrome
Interventions
NGX267
Drug
Lead sponsor
TorreyPines Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Duncansville, Pennsylvania • Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2009 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

NCT03840993
View directory record Official record
Conditions
Endometrial Related Pain
Interventions
MT-2990, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
51
States / cities
Phoenix, Arizona • Sacramento, California • San Diego, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 9, 2026, 10:59 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Intranasal Ketamine Versus Intramuscular Ketamine for Procedural Sedation in Pediatric Patients

NCT01170247
View directory record Official record
Conditions
Sedation
Interventions
Ketamine
Drug
Lead sponsor
University of Iowa
Other
Eligibility
2 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 9, 2026, 10:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 9, 2026, 10:59 AM EDT